Genetic variability of CYP2D6, CYP2B6, CYP2C9 and CYP2C19 genes across the Italian Peninsula

被引:10
|
作者
Carano, Francesco [1 ]
Sarno, Stefania [2 ]
De Fanti, Sara [2 ]
Serventi, Patrizia [2 ,3 ]
Bini, Carla [1 ]
Luiselli, Donata [2 ]
Pelotti, Susi [1 ]
机构
[1] Univ Bologna, Inst Legal Med, Dept Med & Surg Sci, Bologna, Italy
[2] Univ Bologna, Dept Biol Geol & Environm Sci, Mol Anthropol Lab, Bologna, Italy
[3] Alma Mater Studiorum Univ Bologna, Dept Cultural Heritage, Ravenna, Italy
基金
欧洲研究理事会;
关键词
Pharmacogenetics; cytochrome-P450 (CYP) genes; Italian population; genetic variation; geographic structure; GENOTYPE; POLYMORPHISMS; VARIANTS; EXPRESSION; JAPANESE; ENZYMES; ALLELE; PCR;
D O I
10.1080/03014460.2017.1378368
中图分类号
Q98 [人类学];
学科分类号
030303 ;
摘要
Background: Environmental conditions and past migratory events may have shaped genetic heterogeneity of clinically relevant enzymes involved in the phase I metabolism of the most common therapeutic drugs.Aim: To investigate the genetic variability of CYP2D6, CYP2B6, CYP2C19 and CYP2C9 across the Italian Peninsula, by sampling only ancestrally and geographically homogeneous individuals from northern, central and southern Italy.Subjects and methods: A total of 25 SNPs were genotyped in 174 unrelated Italian individuals by means of multiplex PCR and minisequencing reactions. CYP2D6 genotypic data were used to predict phenotypes and the phylogenetic relationships among reconstructed haplotypes were represented by means of a Median Joining Network.Results: Pairwise Fisher Exact tests revealed significant differences between northern and southern Italy in the distribution of CYP2C19 genotypes, with the CYP2C19*2 allele appearing over-represented in northern Italy. Likewise, significant differences in the distribution of CYP2D6 genotypes (*4/*3, *4/*4 and *6/*4) responsible for the poor metabolizer phenotype were observed in northern with respect to both central and southern Italy.Conclusions: The north-south structuring pattern showed by CYP2D6 and CYP2C19 underline how a deeper knowledge of the geographic distribution of alleles may improve clinical practice and help to avoid hypothetical bias in drug trials.
引用
收藏
页码:66 / 71
页数:6
相关论文
共 50 条
  • [21] The pharmacogenetics of CYP2D6 and CYP2C19 in a case series of antidepressant responses
    Kee, Ping Siu
    Maggo, Simran D. S.
    Kennedy, Martin A.
    Chin, Paul K. L.
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [22] CYP2C9, CYP2C19, CYP2D6 and CYP3A5 polymorphisms in South-East and East Asian populations: A systematic review
    Dorji, Palden Wangyel
    Tshering, Gyem
    Na-Bangchang, Kesara
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2019, 44 (04) : 508 - 524
  • [23] Refractoriness in Schizophrenia is not Associated with Cyp2d6 and Cyp2c19 Genotypes
    van de Bilt, Martinus T.
    Prado, Carolina M.
    Ojopi, Elida P. B.
    Zanetti, Marcus V.
    Loch, Alexandre A.
    Sousa, Rafael A. T.
    Machado-Vieira, Rodrigo
    Gattaz, Wagner F.
    BIOLOGICAL PSYCHIATRY, 2012, 71 (08) : 158S - 159S
  • [24] Association between CYP2C19 and CYP2B6 phenotypes and the pharmacokinetics and safety of diazepam
    Zubiaur, Pablo
    Figueiredo-Tor, Laura
    Villapalos-Garcia, Gonzalo
    Soria-Chacartegui, Paula
    Navares-Gomez, Marcos
    Novalbos, Jesus
    Matas, Miriam
    Calleja, Sofia
    Mejia-Abril, Gina
    Roman, Manuel
    Ochoa, Dolores
    Abad-Santos, Francisco
    BIOMEDICINE & PHARMACOTHERAPY, 2022, 155
  • [25] The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation
    Helsby, Nuala A.
    Hui, Chung-Yee
    Goldthorpe, Michael A.
    Coller, Janet K.
    Soh, May Ching
    Gow, Peter J.
    de Zoysa, Janak Z.
    Tingle, Malcolm D.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 70 (06) : 844 - 853
  • [26] Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations
    Allabi, AC
    Gala, JL
    Desager, JP
    Heusterspreute, M
    Horsmans, Y
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 56 (06) : 653 - 657
  • [27] Characterization CYP1A2, CYP2C9, CYP2C19 and CYP2D6 Polymorphisms Using HRMA in Psychiatry Patients with Schizophrenia and Bipolar Disease for Personalized Medicine
    Yenilmez, Ebru Dundar
    Tamam, Lut
    Karaytug, Onur
    Tuli, Abdullah
    COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, 2018, 21 (05) : 374 - 380
  • [28] Increased carrier prevalence of deficient CYP2C9, CYP2C19 and CYP2D6 alleles in depressed patients referred to a tertiary psychiatric hospital
    Ruano, Gualberto
    Villagra, David
    Rahim, Umme Salma
    Windemuth, Andreas
    Kocherla, Mohan
    Bower, Bruce
    Szarek, Bonnie L.
    Goethe, John W.
    PERSONALIZED MEDICINE, 2008, 5 (06) : 579 - 587
  • [29] The inhibition of CYP1A2, CYP2C9, and CYP2D6 by pterostilbene in human liver microsomes
    Albassam, A. A.
    Ahad, A.
    Alsultan, A.
    Yusufoglu, H. S.
    Foudah, A., I
    Al-Jenoobi, F., I
    PHARMAZIE, 2021, 76 (04): : 155 - 158
  • [30] Genetic contribution of CYP2C9, CYP2C19, and APOE variants in acenocoumarol response
    Nastasi-Catanese, J. A.
    Padilla-Gutierrez, J. R.
    Valle, Y.
    Ortega-Gutierrez, F.
    Gallegos-Arreola, M. P.
    Figuera, L. E.
    GENETICS AND MOLECULAR RESEARCH, 2013, 12 (04) : 4413 - 4421